There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Cooper Co (COO) and Edwards Lifesciences (EW) with bullish sentiments.
Cooper Co (COO)
KeyBanc analyst Matthew Mishan maintained a Buy rating on Cooper Co today and set a price target of $296. The company’s shares closed yesterday at $277.03, close to its 52-week high of $283.18.
According to TipRanks.com, Mishan is a 5-star analyst with an average return of 18.5% and a 75.5% success rate. Mishan covers the Healthcare sector, focusing on stocks such as Cantel Medical Corp, Becton Dickinson, and Steris Corp.
Currently, the analyst consensus on Cooper Co is a Strong Buy with an average price target of $294, implying a 6.1% upside from current levels. In a report released today, Piper Jaffray also maintained a Buy rating on the stock with a $300 price target.
.
See today’s analyst top recommended stocks >>
Edwards Lifesciences (EW)
Morgan Stanley analyst David Lewis maintained a Buy rating on Edwards Lifesciences today and set a price target of $180. The company’s shares closed yesterday at $163.33.
According to TipRanks.com, Lewis is a 5-star analyst with an average return of 12.1% and a 69.9% success rate. Lewis covers the Healthcare sector, focusing on stocks such as Boston Scientific Corp, Zimmer Biomet Holdings, and Baxter International.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Edwards Lifesciences with a $167.43 average price target, representing a 2.5% upside. In a report issued on November 30, Cowen & Co. also assigned a Buy rating to the stock with a $190 price target.
.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
